Page 13 - Stefan Oschmann News Today : Breaking News, Live Updates & Top Stories | Vimarsana

10:00 – 11:00 am 2020 was a year like no other as the annual biopharma M&A total fell to the lowest level since EY began publishing its annual M&A Firepower report in 2013. In the first half of the year, the specter of COVID-19 deterred deals; as economies started to reopen, persistently high valuations were another reason many buyers remained on the fence. In the midst of such uncertainty, an innovation narrative emerged, with growing evidence of the power of new technologies, from antibody drug conjugates in oncology to RNA-based vaccines. These new innovations sparked many of 2020’s most notable deals and are sure to be important in the future. In this one hour panel discussion, we will discuss the current state of biopharma dealmaking and its implications for 2021 with M&A leaders from across the industry.

David rhewStefan oschmannPeter behnerJoseph devivoPiper sandlerSusan moranoJohn babittOrlando seraniBrian malkinJohn youngChristopher clearyJanssen pharmaceutical companies of johnsonMerck kgaHealth systemsBristol myers squibbMedtech panel